Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Inhibrx Biosciences, Inc. (INBX : NSDQ)

• Company Description    Inhibrx Inc. is a clinical-stage biopharmaceutical company. It focused on developing a broad pipeline of novel biologic therapeutic candidates in oncology and orphan diseases. Inhibrx Inc. is based in SAN DIEGO. Number of Employees: 161

• Price / Volume Information    Yesterday's Closing Price: $79.00 Daily Weekly Monthly 20 Day Moving Average: 232,534 shares Shares Outstanding: 14.54 (millions) Market Capitalization: $1,148.95 (millions) Beta: 1.34 52 Week High: $94.57 52 Week Low: $10.81 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -9.62% -9.47% 12 Week 125.71% 122.07% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 11025 N. TORREY PINES ROAD SUITE 140 - LA JOLLA,CA 92037 USA ph: 858-795-4220 fax: - ir@inhibrx.com https://inhibrx.com

• General Corporate Information    Officers Mark P. Lappe - Chief Executive Officer and Chairman Kelly D. Deck - Chief Financial Officer Jon Faiz Kayyem - Director Douglas G. Forsyth - Director Kimberly Manhard - Director Peer Information Inhibrx Biosciences, Inc. (CORR.) Inhibrx Biosciences, Inc. (RSPI) Inhibrx Biosciences, Inc. (CGXP) Inhibrx Biosciences, Inc. (BGEN) Inhibrx Biosciences, Inc. (GTBP) Inhibrx Biosciences, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 45720N103 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/16/26 Share - Related Items Shares Outstanding: 14.54 Most Recent Split Date: (:1) Beta: 1.34 Market Capitalization: $1,148.95 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/16/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 31.07 Price/Cash Flow: 0.68 Price / Sales: - EPS Growth vs. Year Ago Period: 19.72% vs. Previous Quarter: -23.24% Sales Growth vs. Year Ago Period: 1,200.00% vs. Previous Quarter: -% ROE 12/31/25 - - 09/30/25 - -186.06 06/30/25 - -137.83 ROA 12/31/25 - - 09/30/25 - -76.30 06/30/25 - -76.31 Current Ratio 12/31/25 - - 09/30/25 - 4.49 06/30/25 - 4.98 Quick Ratio 12/31/25 - - 09/30/25 - 4.49 06/30/25 - 4.98 Operating Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Net Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Pre-Tax Margin 12/31/25 - - 09/30/25 - -11,077.43 06/30/25 - -11,692.29 Book Value 12/31/25 - - 09/30/25 - 2.54 06/30/25 - 4.74 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - - 09/30/25 - 2.71 06/30/25 - 1.45 Debt-to-Capital 12/31/25 - - 09/30/25 - 73.07 06/30/25 - 59.15

Powered by Zacks Investment Research ©